Skip to main content
. 2024 Sep 30;15(11):2429–2441. doi: 10.1007/s13300-024-01650-2

Fig. 1.

Fig. 1

Study overview. R on-site screening; V1 baseline visit with the handout of study supplies, start and training of insulin therapy and SMS service, HbA1c testing, and questionnaire administration. V2 Clarification of any questions and documenting any adverse events or device deficiencies, if any. V3 documentation of FBG stable in range, V4 HbA1c testing, data download, questionnaires, and documentation and documenting any adverse events or device deficiencies, V5 Documenting any adverse events or device deficiencies, if any. BOT basal oral-supported therapy. SMS Short Messaging Service; ICF informed consent form; FBG fasting blood glucose